Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability

Ecallantide (Kalbitor®, Dyax Corporation) is a highly specific recombinant plasma kallikrein inhibitor developed for treatment of hereditary angioedema (HAE). Advantages of this agent over plasma-derived treatments are that it poses no risk of viral contamination, is highly selective, has a quick onset of action and can be administered subcutaneously. In clinical trials, ecallantide appears to be a safe and effective drug useful for the treatment of HAE patients suffering from an acute attack. Ecallantide was found to be superior compared with placebo in relieving symptoms, decreasing the severity of attacks and shortening the duration of attacks. The primary safety concern appears to be related to hypersensitivity reactions. Phase IV postmarketing surveillance studies to monitor the incidence of these reactions will be implemented by the company now that the drug has been US FDA approved.

[1]  J. Bernstein,et al.  Current and Emerging Management Options for Hereditary Angioedema in the US , 2012, Drugs.

[2]  B. Zuraw.  The Pathophysiology of Hereditary Angioedema , 2010, The World Allergy Organization journal.

[3]  K. Wyrwich,et al.  Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema , 2009, Quality of Life Research.

[4]  M. Cicardi,et al.  C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. , 2009, Trends in molecular medicine.

[5]  J. Bernstein,et al.  Successful use of C1 inhibitor during mitral valve replacement surgery with cardiopulmonary bypass. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  B. Zuraw.  Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  J. Bernstein.  Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  A. Sheffer,et al.  Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  Lynda Schneider,et al.  Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. , 2007, The Journal of allergy and clinical immunology.

[10]  P. Schlattmann,et al.  Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.

[11]  T. Craig,et al.  Fresh frozen plasma for the treatment of hereditary angioedema. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  J. Levy,et al.  The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema , 2006, Expert opinion on investigational drugs.

[13]  A. Lehmann.  Ecallantide (Dyax/Genzyme). , 2006, Current opinion in investigational drugs.

[14]  T. Caballero,et al.  Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. , 2006, Journal of Allergy and Clinical Immunology.

[15]  M. Gompels,et al.  C1 inhibitor deficiency: diagnosis , 2005, Clinical and experimental dermatology.

[16]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[17]  B. Zuraw.  Current and future therapy for hereditary angioedema. , 2005, Clinical immunology.

[18]  Anthony Williams,et al.  DX-88 and HAE: a developmental perspective. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[19]  M. Cicardi,et al.  Local bradykinin generation in hereditary angioedema. , 1999, The Journal of allergy and clinical immunology.

[20]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[21]  J. Atkinson,et al.  Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. , 1975, The Journal of allergy and clinical immunology.